INTRODUCTION
Warfarin is one of the most widely used oral anticoagulants in the treatment and prophylaxis of arterial and venous thromboembolic diseases [1, 2] . The warfarin has a narrow therapeutic range, its dosage is affected by genetic and non-genetic factors [3, 4] . Non-genetic factors are gender, age, diet, race, concomitant drugs, body surface area (BSA) [5] . Genetic factors such as polymorphisms in the cytochrome P450 (CYP2C9), (CYP4F2) and the vitamin K epoxide reductase complex 1 (VKORC1) genes may also influence patient's response to warfarin [6, 7] . Warfarin treatment is associated with interindividual variability in maintaining its effective dose, therapeutic warfarin doses differ between patients in 15-20 times [8] . High interindividual variability in warfarin doses has led to development of algorithms, scales, calculators for the selection of warfarin doses for anticoagulant therapy. Multiple genotype-based warfarin dosing algorithms have been published, however, the most cited is the Gage algorithm, since there is a simple calculator and it is freely available online (www.warfarindosing.org) [9] . The Gage algorithm is based on data from large, predominantly Caucasian, populations. This algorithm was derived from a population of over 1.000 patients, 83 % of which were Caucasians, and 2 % belonged to different races [10] . Little information is available on performance of published warfarin pharmacogenetic algorithms, and there is no data on performance of the Gage algorithm in Russian populations.
Aim of this study was to compare the actual warfarin dose (AWD) to the calculated warfarin dose (CWD), using the algorithm in two ethnic groups: Caucasians and Asians.
MATERIALS AND METHODS
The study was conducted from 2013 to 2018 years. We included patients with stable warfarin therapy. The study included 114 patients: 66 Caucasians and 48 Asians, 61 (53.51 %) men and 53 (46.49 %) women, mean age 60.91 ± 12.34 years. These patients were living in the Asian part of Russia (Irkutsk region and the Republic of Buryatia). They were diagnosed with: atrial fibrillation -92 (80.7 %), coronary artery disease -7 (6.14 %), arrhythmia -3 (2.6 %), thrombosis in a patient's medical history -8 (7.01 %), no data -4 (3.5 %). We had accessed the data from medical history, which included: smoking -21 (18.42 %), taking amiodarone -14 (12.28 %), and statins -67 (58.77 %). Actual warfarin maintenance dose was defined as a stable dose for which the international normalized ratio (INR) measurements were within the therapeutic range (2-3) for the same mean daily dose during the last three clinic visits and is indicated as AWD in this study.
We excluded the patients if they had hepatic, thyroid (hypotheriosis or hyperthyreosis), renal diseases, decompensated heart failure, and patients taking warfarin interacting drugs, including Azoles and Trimethoprim-Sulfamethoxazole, because these drugs affected the metabolism of warfarin, and patients who did not comply with oral anticoagulant therapy (OAT).
Performance or percentage of compliance of the Gage algorithm was compared by calculating the percentage of patients, whose CWD was within 20 % of AWD, and mean absolute error (MAE). We defined MAE as the mean value of the difference between CWD and AWD. We chose the percentage of patients within 20 % of AWD (the percentage within 20 %), because a change in a warfarin dose greater than 20 % may be considered clinically significant, and this change was used in other studies [11, 12] .
The study was approved by the local Research Ethics Committee of Scientific Сentre for Family Health and Human Reproduction Problems, and all patients provided informed consent to participate in the study.
Four ml of venous blood were collected in EDTA tube from each participant and processed for genomic DNA extraction. The subjects were genotyped for CYP2C9 (*1,*2,*3), and CYP4F2 (1347 C>T) and VKORC1 (1639 G>A) by real-time polymerase chain reaction (RT-PCR) using Pharmacogenetics Warfarin reagent kits (DNA technology, Russia).
RESULTS
We calculated CWD for each patient using the Gage algorithm (Table 1) . Results showed that the algorithm produced similar performance between CWD and AWD, observed in real clinical practice, and in two ethnic groups taking warfarin. We discovered that Asian patients had mean AWD = 3.58 ± 1.5 and, when compared with mean CWD = 3.76 ± 1.08, we found no significant differences (p = 0.502). Mean AWD of the Caucasian patients was 4.02 ± 1.9, so we did not find significant differences by comparing it with mean CWD = 4.56 ± 1.49 (p = 0.072).
Генетика, протеомика и метаболомика
The stable therapeutic dose was predicted with similar accuracy for two ethnic groups with MAE = 1.33 mg/day (SE = 0.16) in our Caucasian cohort and with MAE = 1.02 mg/ day (SE = 0.16) in the Asian one (p = 0.184). We calculated the percentage of patients, AWD of who did not differ from CWD by more or less 20 % in the Caucasian cohort (40.9 %) and similarly in the Asian cohort (39.58 %), (p = 0,959). Comparison of the pharmacogenetic warfarin dosing using the Gage algorithm in two ethnic groups (Caucasians and Asians) of the Russian population showed that population overall performance of the algorithm was similar.
DISCUSSION
The history of the use of oral anticoagulants has more than half a century. Their effectiveness in the prevention of cardioembolic stroke was confirmed by clinical studies. However, warfarin therapy has several limitations: a "narrow therapeutic window", unpredictability of the anticoagulant response, interactions between food and drugs, and the need for regular international normalized ratio (INR) monitoring to maintain the effectiveness and safety of treatment. All the above stated determined the search for optimization of warfarin anticoagulant therapy, including the development of algorithms for drug therapy. One of the widely used algorithms is the calculator, developed by Gage et al. of the University of Washington in 2008.
In this study, we assessed the predictive accuracy of the pharmacogenetic warfarin dosing using the Gage algorithm, in real clinical practice in patients, living in the Asian part of Russia. The results indicated that the percentage within 20 % in the general population was 42.2 %. No differences between doses were found in Caucasians and Asians (40.9 % and 39.58 % respectively, p = 0.959) . Data from similar studies are variable. In previous study of E. Kropachyova et al., in 283 patients from the Russian population living in Moscow, Arkhangelsk, Vyatka, Nizhny Novgorod, Novosibirsk, St. Petersburg, Chelyabinsk, the percentage within 20 % was 57 % (we compared the percentage with our own study in the Caucasian population, p = 0.011) [13] . Results, comparable to our data, were demonstrated by the researchers Jaekyu Shin and Diana Cao of the Department of Clinical Pharmacy San Francisco -53.1 % (p = 0.071) [12] . Studies, conducted in the Turkish population, showed that the percentage within 20 % was 29 %, and MAE = 2.25 (SE = 0.23), which was significantly different from our results (p = 0.009) [14] . In the Asian population, we found that percentage within 20 % was 39.58 %, which was comparable with the data of Shin et al., for a sample of Asian patients -48.1 % (p = 0.33). The results indicated the low prognostic significance of the Gage algorithm, possibly due to differentiation of functional significance of warfarin metabolizing genes and their involvement in the formation of phenotypes in different racial, ethnic and territorial populations.
CONCLUSIONS
The Gage algorithm was based on a mixed population and therefore we did not get the predictive accuracy of significant differences in two ethnic groups (Caucasians and Asians) of the Russian population. In conclusion, despite performance limitation of the current warfarin pharmacogenetic dosing using the Gage algorithm, close INR monitoring is essential. 
